We have previously developed an antibody fusion protein composed of a mouse/human chimeric IgG3 specific for the human transferrin receptor genetically fused to avidin (anti-hTfR IgG3-Av) as a universal delivery system for cancer therapy. This fusion protein efficiently delivers biotinylated FITC into cancer cells via TfR-mediated endocytosis. In addition, anti-hTfR IgG3-Av alone exhibits intrinsic cytotoxic activity and interferes with hTfR recycling, leading to the rapid degradation of the TfR and lethal iron deprivation in certain malignant B-cell lines. We now report on the cytotoxic effects of a conjugate composed of anti-hTfR IgG3-Av and biotinylated saporin 6 (b-SO6), a toxin derived from the plant Saponaria officinalis that inhibits protein synthesis. Conjugation of anti-hTfR IgG3-Av with b-SO6 enhances the cytotoxic effect of the fusion protein in sensitive cells and also overcomes the resistance of malignant cells that show low sensitivity to the fusion protein alone. Our results show for the first time that loading anti-hTfR IgG3-Av with a biotinylated toxin enhances the cytotoxicity of the fusion protein alone. These results suggest that anti-hTfR IgG3-Av has great potential as a therapeutic agent for a wide range of applications due to its intrinsic cytotoxic activity plus its ability to deliver biotinylated molecules into cancer cells.
Introduction
The human transferrin receptor (hTfR) is a type II transmembrane glycoprotein involved in cellular iron uptake, iron homeostasis, and the regulation of cell growth and proliferation (reviewed in ref. 1). The hTfR is an attractive target for the delivery of cytotoxic agents due to its increased expression in malignant compared with normal cells, its extracellular accessibility, and its constitutive endocytosis cycle (reviewed in refs. 1, 2). Our group previously developed an antibody-avidin fusion protein targeting the hTfR to serve as a universal vector for the delivery of biotinylated therapeutic agents into cancer cells (3, 4) . Anti-hTfR IgG3-Av consists of a mouse/human chimeric IgG3 genetically fused to chicken avidin at the carboxy terminus of the C H 3 domain of the heavy chain (g3; Fig. 1A ). Fast protein liquid chromatography analysis of the fusion protein suggests that the protein is a dimer in solution (ref. 3 ; Fig. 1B ), a structure that is expected due to the noncovalent tetrameric nature of avidin (5) . We have previously shown that this antibody-avidin fusion protein efficiently delivers a biotinylated fluorochrome (FITC) into cancer cells by receptor-mediated endocytosis (3) . Surprisingly, anti-hTfR IgG3-Av was found to exhibit intrinsic cytotoxic activity in certain malignant B-cell lines and primary myeloma cells (4) . The antibody-avidin fusion protein interferes with the normal cycling pathway of the hTfR and directs the hTfR into a LAMP-1 -positive compartment where it seems to be degraded. Therefore, in anti-hTfR IgG3-Av -treated cells, surface hTfR expression decreases, resulting in lethal iron deprivation and apoptosis (4) . In more recent studies, we have shown that anti-hTfR IgG3-Av specifically targets cells expressing hTfR1, but not hTfR2, a second receptor that shares 45% identity and 66% similarity with the extracellular domain of hTfR1 (1) . 6 The cytotoxic properties of anti-hTfR IgG3-Av can potentially be enhanced by its conjugation to biotinylated cytotoxic agents, including bacterial or plant toxins. Among them, a promising compound is the plant toxin saporin, produced by Saponaria officinalis. Saporin is a member of the ribosome-inactivating protein family of toxins (reviewed in ref. 6 ). The combination of saporin with various delivery systems has shown, in vitro and in vivo, that saporin immunotoxins [including genetic fusion proteins (7 -9) and chemical conjugates (8, 10 -13) ] are effective antitumor agents. In fact, the potential anticancer benefits of saporin immunotoxins has been shown in phase I clinical trials for the treatment of advanced refractory Hodgkin's disease (anti-CD30 murine monoclonal antibody chemically conjugated to saporin; ref. 14) and for advanced-stage B-cell lymphoma (bispecific antibodies specific for saporin and CD22; ref. 15) . Immunotoxins targeting the hTfR, via chemical conjugation with transferrin (16) or an anti-hTfR antibody (17) , have also shown in vitro cytotoxic effects in malignant cells.
Although saporin immunotoxins have been successful antitumor agents, the immunotoxins described above have some disadvantages. Chemical conjugates have many drawbacks, including a lack of homogeneity, whereas the use of fusion proteins requires that a different protein be created for each application. In addition, there can be a decrease or loss of activity of one or both partners. The antihTfR IgG3-Av fusion protein overcomes these limitations and can be used as a universal delivery vector, which eliminates the need to make specific constructs for each application. Anti-hTfR IgG3-Av also has the advantage of having multiple modes of antitumor activity (intrinsic proapoptotic, delivery of therapeutic agents, and possible Fc effector functions). We now report the effective delivery into malignant cells of an active toxin, biotinylated saporin 6 (b-SO6), by anti-hTfR IgG3-Av. This report provides the initial proof-of-principle that conjugation of anti-hTfR IgG3-Av with a biotinylated toxin enhances its cytotoxicity and also overcomes the resistance in malignant cells that show low sensitivity to anti-hTfR IgG3-Av. The mechanism of the cytotoxicity induced by the anti-hTfR IgG3-Av/b-SO6 complex is also addressed.
Materials and Methods

Antibodies, Antibody Fusion Proteins, and Toxin Conjugates
The mouse/human chimeric antibodies specific for the hapten dansyl [5-dimethylamino naphthalene-1-sulfonyl chloride (anti-DNS IgG3); refs. 18, 19] , the hTfR (anti-hTfR IgG3; ref. 3) , and the antibody avidin fusion proteins [anti-DNS IgG3-Av (negative isotype control) and anti-hTfR IgG3-Av] have been described previously (3, 20) . Briefly, chicken avidin was genetically fused to the C H 3 domain of anti-DNS IgG3. To construct the anti-hTfR IgG3-Av fusion protein, the heavy and light chain variable regions of anti-DNS IgG3-Av were substituted for the variable regions of the murine monoclonal anti-human TfR IgG1 antibody 128.1 (3, 21) . Anti-DNS IgG3-Av and anti-hTfR IgG3-Av were expressed in murine myeloma cells, which were then expanded in roller bottles (Fisher Scientific). The antibody fusion proteins were purified from cell culture supernatants using affinity chromatography (3, 22) . All fractions were tested for fusion protein integrity and purity in 5% phosphate gels under nonreducing conditions. Fractions containing purified protein were pooled and dialyzed into protein buffer [150 mmol/L NaCl, 50 mmol/L Tris-HCl (pH 7.8)]. Protein concentrations were determined by bicinchoninic acid -based protein assay (BCA Protein Assay, Pierce Biotechnology, Inc.; refs. 3, 22). Antibody fusion proteins were then stored at À80jC in snap-frozen aliquots.
Saporin belongs to a gene family that consists of many isoforms. SO6 is isolated from the seed of the S. officinalis plant and has been shown to contain higher catalytic activity than another isoform, saporin 5 (23) . The custom conjugate b-SO6 was purchased from Advanced Targeting Systems, which was purified from the seed of the plant as previously described (24, 25) and conjugated to Biotin-HPDP (Pierce Biotechnology, Inc.) according to manufacturer's instructions. This custom conjugate was manufactured with 1.1 moles of biotin per 1 mole of saporin to avoid the formation of aggregates when complexed to the avidin fusion proteins. Conjugation of b-SO6 with the antibody-avidin fusion proteins was carried out on ice for 30 min at a 1:1 molar ratio before the addition of cell culture medium.
Cell Lines and Primary Cells IM-9 (an EBV-transformed lymphoblastoid cell line isolated from the peripheral blood of a patient with multiple myeloma) and U266 (a lymphoblast cell line isolated from the peripheral blood of a patient with myeloma/plasmacytoma) were purchased from the American Type Culture Collection. The cell lines were maintained in RPMI 1640 (Invitrogen Corporation) supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Inc.) and grown in 5% CO 2 at 37jC. Cell images were captured using a Zeiss Axiovert 40 CFL PlasDIC Inverted Microscope using a Â20 objective (Mikron Instruments, Inc.) and a Canon PowerShot A620 digital camera (Mikron Instruments).
Bone marrow aspirates from either a patient with multiple myeloma or with plasma-cell leukemia, a more aggressive variant of multiple myeloma (26) Caspase Activity Assays IM-9 and U266 cells were seeded at a density of 10 4 per well (total volume per well, 200 AL) of black, clearbottomed 96-well tissue culture plates (Fisher Scientific). Cells were treated with 10 nmol/L of the various antibodies, antibody fusion proteins, and toxin conjugates for the indicated time points. The plates were then centrifuged at 250 Â g for 10 min in an Allegra X-15R Centrifuge (Beckman Coulter, Inc.). One hundred microliters of the supernatant were carefully removed and the remaining cells were assayed for caspase activity using fluorogenic substrates in a one-step assay as described previously (4, 27) . At each time point, 50 AL of one-step assay buffer [1.5% NP40, 0.3% CHAPS, 30% sucrose, 30 mmol/L MgCl 2 , 150 mmol/L KCl, 450 mmol/L NaCl, 150 mmol/L HEPES, 1.2 mmol/L EGTA, 30 mmol/L DTT, 3 mmol/L phenylmethylsulfonyl fluoride (pH 7.4)] containing 150 Amol/L of the fluorogenic substrate being tested were added to each well and incubated for 1 h at 37jC in 5% CO 2 . Fluorogenic substrates specific for caspase-2 (Ac-VDVAD-AMC), caspase-9 (Ac-LEHD-AMC), caspase-8 (Ac-IETD-AMC), caspase-3 and caspase-7 (Ac-DEVD-AMC), and caspase-3 (Ac-DMQD-AMC; all from Axxora Life Sciences, Inc.) were used. The plate was then read at excitation and emission wavelengths of 380 and 460 nm, respectively, in a DTX880 Multimode Detector (Beckman Coulter). Background fluorescence, measured in wells containing only medium and one-step assay buffer with substrate (no cells), was subtracted from each sample. To calculate the fold increase in activation of each caspase, the average relative fluorescence intensity of the treated wells was divided by the average relative fluorescence intensity of the negative control wells. For caspase inhibition studies, cells were Human Colony-Forming Assay Frozen human bone marrow mononuclear cells were purchased from StemCell Technologies and thawed following the manufacturer's instructions. The mononuclear cells were treated with buffer alone (negative control), 1 nmol/L anti-hTFR IgG3-Av, or 1 nmol/L anti-hTFR IgG3-Av/b-SO6 for 1 h in Iscove's modified Dulbecco's medium containing 10% fetal bovine serum in 5% CO 2 at 37jC. The cells were then washed thrice in Iscove's modified Dulbecco's medium containing 2% fetal bovine serum (StemCell Technologies) and plated in MethoCult medium as instructed by the manufacturer. Cells were plated in quadruplicate (at a density of 2 Â 10 4 per 35-mm dish) in MethoCult GF H4434 (''Complete'' Methylcellulose Medium with Recombinant Cytokines and Erythropoietin). The cells were then incubated for 14 days at in 5% CO 2 at 37jC. The number of colony-forming unit -erythroid (mature erythroid progenitors), burst-forming unit -erythroid (more primitive progenitor than colony-forming unit -erythroid), and colony-forming unit -granulocyte/macrophage was determined using an Olympus CK2 inverted microscope and the criteria defined by StemCell Technologies for each colony type. The average number of colonies was determined from quadruplicate samples.
Flow Cytometry CD34 + cells were purchased from StemCell Technologies. These cells showed a 97% purity as reported on the technical data sheet. The CD34 + cells were thawed according to the manufacturer's instructions. IM-9, U266, and CD34 + cells (2 Â 10 5 ) were incubated for 15 min on ice with either phycoerythrin-conjugated mouse IgG2a n isotype control or phycoerythrin-conjugated mouse anti-human CD71 (hTfR) monoclonal antibodies (BD Biosciences). Cells were then washed and analyzed on a FACScan flow cytometer (BD Biosciences). Data were analyzed using the CELLQuest software (BD Biosciences).
Statistical Analysis All statistical analyses were done using Microsoft Excel 2000 SR-1 Standard. Significant differences were calculated using the Student's t test (unpaired samples, two-tailed, unequal variance). P values <0.05 were considered to be significant.
Results
Conjugation of Anti-hTfRIgG3-Av with b-SO6 Results in Significant Enhancement of the Cytotoxic Effects of the Fusion Protein Alone
We previously showed that a panel of malignant hematopoietic cell lines shows various sensitivities to anti-hTfR IgG3-Av (4). Therefore, we chose one highly sensitive cell line (IM-9) and one cell line with low sensitivity (U266) to use in our studies for targeted delivery of b-SO6. As expected, the parental antibody anti-hTfR IgG3 was slightly inhibitory to the growth of IM-9 cells, whereas anti-hTfR IgG3-Av elicited significant growth inhibition to IM-9 but not to U266 cells ( Fig. 2A ; left panels). When cells were treated with anti-hTfR IgG3-Av/b-SO6 ( Fig. 2A, right panels) . When primary myeloma cells isolated from bone marrow aspirates of two patients were treated with anti-hTfR IgG3-Av alone or anti-hTfR IgG3-Av/b-SO6, the conjugate showed higher growth-inhibitory effects than the antibody-avidin fusion protein alone (Fig. 2B) .
Morphologic studies were carried out to determine if anti-hTfR IgG3-Av induced cell death or simply blocked proliferation. In IM-9 cells, anti-hTfR IgG3 showed that some cell death did occur (Fig. 2C, top) . Cells treated with anti-hTfR IgG3-Av showed even more cell death than those treated with the parental antibody as expected from our previous studies. U266 cells treated with anti-hTfR IgG3, anti-hTfR IgG3-Av, or anti-DNS IgG3-Av/b-SO6 did not exhibit morphologic changes compared with cells treated with buffer alone (Fig. 2C, bottom) . However, in both IM-9 and U266 cells treated with anti-hTfR IgG3-Av/ b-SO6, the cell number and the morphology of the remaining cells show that the treatment resulted in the massive induction of cell death. These results indicate that the effects induced by anti-hTfR IgG3-Av/b-SO6 are not only due to a block in proliferation, but also due to the induction of cell death. To study the stability of anti-hTfR IgG3-Av/b-SO6, the complex was incubated in RPMI medium containing 10% fetal bovine serum for various times at 37jC. The antiproliferative effect of the complex was then monitored by incubation with IM-9 (Fig. 2D, left) or U266 (Fig. 2D, right) cells for 48 h. Anti-hTfR IgG3-Av/b-SO6 is highly stable as evidenced by its ability to block proliferation in both IM-9 and U266 cells even after incubation in medium for an extended period. A slight loss of activity (10% in U266 cells and 16% in IM-9 cells) was only observed after the 6-day incubation period.
To further study the cell death induced by the anti-hTfR IgG3-Av/b-SO6 complex, we examined the change in cell membrane composition and disruption by monitoring Annexin V and propidium iodide staining. Apoptotic cells are reported as both early (Annexin V + /propidium iodide À ) and late apoptotic cells (Annexin V + /propidium iodide + ). In IM-9 cells, anti-hTfR IgG3 induced apoptosis only at low levels ( Fig. 3, left) . Anti-hTfR IgG3-Av induced high levels of apoptosis at 48 h with a total Annexin V + of 60.5% that increased to 78.1% at 72 h. However, higher levels of apoptosis were induced by anti-hTfR IgG3-Av/b-SO6. At 24 h, the total Annexin V + was 32%, which increased to 78.6% at 48 h and further increased to 92% at 72 h. In U266 cells, only anti-hTfR IgG3-Av/b-SO6 showed strong induction of apoptosis with a total of 39.7% Annexin V + cells at 24 h, 57.9% at 48 h, and 71.9% at 72 h (Fig. 3, right) . It should also be noted that in both cell lines treated with anti-hTfR IgG3-Av/b-SO6, the population of cells in the lower left quadrant shows a slight shift to the right, suggesting that all of the cells are becoming Annexin V + . Anti-DNS IgG3-Av/b-SO6 only induced a low level of apoptosis in both cell lines over time. Anti-DNS IgG3, anti-DNS IgG3-Av, and b-SO6 alone did not induce apoptosis in either cell line (data not shown).
Targeting of the hTfR Is Required for Anti-hTfR IgG3-Av/b-SO6^Induced Toxicity
The fact that only marginal cytotoxic effects were observed with a nontargeted anti-DNS IgG3-Av/b-SO6 (Fig. 4) . Both 10-fold (P < 0.001) and 100-fold (P < 0.001) excess anti-hTfR IgG3-Av significantly blocked the cytotoxic effects of the complex. One thousand -fold excess anti-hTfR IgG3-Av almost completely blocked the cytotoxicity induced by 0.1 nmol/L anti-hTfR IgG3-Av/ b-SO6 (P < 0.01). These results are consistent with the internalization of the anti-hTfR IgG3-Av/b-SO6 complex through the interaction of the antibody with the cell surface TfR.
Treatment with Anti-hTfR IgG3-Av/b-SO6 Results in the Inhibition of Protein Synthesis
Because the mechanism of cytotoxicity of saporin is through the inactivation of the ribosome, we evaluated the ability of delivered b-SO6 to inhibit protein synthesis in both IM-9 and U266 cells. The kinetics of protein synthesis inhibition were very similar to the kinetics of the antiproliferative effects induced by treatment with the antihTfR IgG3-Av/b-SO6 complex. In IM-9 cells treated with 1 nmol/L anti-hTfR IgG3-Av/b-SO6, protein synthesis was completely blocked by 48 h (99% blockage, P < 0.001; Fig. 5A ). Inhibition of protein synthesis occurred more slowly in U266 cells (Fig. 5B) ; however, significant inhibition was also observed by 48 h. No inhibition of protein synthesis was observed in cells treated with the control treatments. These results indicate that some or all of the b-SO6 delivered by anti-hTfR IgG3-Av remains active after its internalization.
The Cytotoxicity Induced by Anti-hTfR IgG3-Av/ b-SO6 Is Not Due to Iron Deprivation
The cytotoxicity of anti-hTfR IgG3-Av in two highly sensitive cell lines, ARH-77 and IM-9, was previously shown to be due to iron deprivation and could be blocked by the addition of FAC (4). To determine whether iron deprivation plays a role in anti-hTfR IgG3-Av/b-SO6 -induced cell death, we coincubated the complex with 25 Amol/L FAC. As expected, FAC significantly blocked the cell death induced by anti-hTfR IgG3-Av alone in IM-9 cells (Fig. 6A) . However, FAC was unable to inhibit the antiproliferative effects induced by the anti-hTfR IgG3-Av/ b-SO6 complex in IM-9 or U266 (Fig. 6) , indicating that the cytotoxicity of the complex is mediated by b-SO6. We monitored the activation of several caspases to determine the apoptotic pathway that was induced by the anti-hTfR IgG3-Av/b-SO6 complex. Caspase-8 is a key initiator caspase for the death receptor (extrinsic) pathway of apoptosis, whereas caspase 9 is the initiator of the mitochondrial (intrinsic) pathway (29) . Caspase-3 is a key effector caspase and is activated in both the intrinsic and extrinsic apoptotic pathways. Caspase-2 is also an initiator caspase and is activated in response to UV irradiation and DNA damage (29) . In U266 cells, treatment with anti-hTfR IgG3-Av alone did not result in a significant increase in caspase activation (Fig. 7A, top left) , as expected because these cells show resistance to the cytotoxic effects of the fusion protein ( Figs. 2 and 3; ref. 4 ). An increase in activation of caspase-2, caspase-3, caspase-8, and caspase-9 was observed at late time points in IM-9 cells treated with anti-hTfR IgG3-Av (Fig. 7A, top right) , also confirming previous results that showed simultaneous activation of caspase-8, caspase-9, and caspase-3 in the sensitive ARH-77 cell line (4). Anti-DNS IgG3-Av/b-SO6 induced low levels of caspase activation at late time points in both cell lines (Fig. 7A, middle) , which is consistent with the low level of apoptotic induction observed in IM-9 and U266 at late time points (Fig. 3) . High levels of caspase-2 and caspase-3 are observed in both cells lines treated with anti-hTfR IgG3-Av/b-SO6 (Fig. 7A, bottom) . This activation of caspase-2 and caspase-3 occurs before, and at higher levels, than caspase-8 and caspase-9. These results suggest that in IM-9 cells treated with anti-hTfR IgG3-Av as well as in both IM-9 and U266 cells treated with anti-hTfR IgG3-Av/b-SO6, an alternate apoptotic pathway is induced in which caspase-2 plays a key role.
To determine if caspase activation is a required event in anti-hTfR IgG3-Av/b-SO6 -induced cell death, we treated IM-9 and U266 cells with the pan caspase inhibitor Z-VAD-FMK for 1 h before the addition of the fusion protein alone or the anti-hTfR IgG3-Av/b-SO6 complexes. Cells were also treated with an anti-Fas antibody (with and without Z-VAD-FMK) as a positive control for caspase-dependent cell death (28) . U266 cells are resistant to Fas-mediated cell death (30) , whereas IM-9 cells are sensitive (31) . In both IM-9 and U266 cells, Z-VAD-FMK could not block the inhibition of proliferation induced by anti-hTfR IgG3-Av/ b-SO6 (Fig. 7B) , although it completely blocked caspase activation in these cells (data not shown). However, in IM-9 cells, Z-VAD-FMK was able to restore proliferation in anti-Fas -treated cells. These results indicate that although caspases are activated by anti-hTfR IgG3-Av/b-SO6 treatment, cytotoxicity occurs, at least in part, through a caspase-independent process.
Toxicity of Anti-hTfR IgG3-Av and Anti-hTfR IgG3-Av/ b-SO6 to Hematopoietic Progenitors Because cytotoxicity of both the anti-hTfR IgG3-Av and anti-hTfR IgG3-Av/b-SO6 are observed in malignant hematopoietic cells, normal hematopoietic cells (CD34 + ) may also be vulnerable to these cytotoxic effects. However, a limitation in studying the toxic effects on these progenitor cells is that it is difficult to culture these cells for extended periods in liquid medium. Therefore, it is preferred to test the toxicity to CD34 + cells by the human progenitor colonyforming assay, which allows the cells to be cultured in a semisolid medium containing the required growth factors and cytokines that allow for colony formation. CD34 + cells from healthy donors were incubated with 1 nmol/L antihTfR IgG3-Av alone or complexed to b-SO6 for 1 h in liquid medium. The CD34 + cells were then plated in methylcellulose medium and the number of colony-forming uniterythroid, burst-forming unit-erythroid, and colony-forming unit -granulocyte/macrophage colonies was determined after 14 days. It is important to note that in IM-9 and U266 cells, treatment with 1 nmol/L anti-hTfR IgG3-Av/ b-SO6 for 1 h followed by replacement of cell culture medium and further culture for 48 h results in an inhibition of proliferation similar to that of continuous 48 h treatment with anti-hTfR IgG3-Av/b-SO6 (data not shown). AntihTfR IgG3-Av alone had no effect on colony formation (Table 1) . However, toxicity to all colony types was observed with anti-hTfR IgG3-Av/b-SO6 treatment (Table 1) . Although colony formation was inhibited, formation was not completely blocked. Cell Surface Expression of the hTfR Because we observed some toxicity in hematopoietic progenitor cells treated with anti-hTfR IgG3-Av/b-SO6, we decided to evaluate the level of hTfR expression on the surface of CD34 + cells as well as IM-9 and U266 cells. This analysis was conducted simultaneously in all three cell types by flow cytometry. Both IM-9 and U266 cells show high hTfR expression (Fig. 8) . CD34 + cells are a heterogeneous population in which the majority of cells show hTfR expression (Fig. 8) . However, some cells show low or no expression of the hTfR as evidenced by significant overlap with cells stained with a control antibody.
Discussion
In the present study, we provide the initial proof-ofprinciple that anti-hTfR IgG3-Av has dual functional activity due to its intrinsic cytotoxic activity and its ability to deliver active biotinylated agents into targeted cells. Conjugation of anti-hTfR IgG3-Av with b-SO6 enhances the cytotoxic effects of anti-hTfR IgG3-Av in sensitive cells (IM-9) and can also overcome the resistance observed in cells that show low sensitivity to the effects of anti-hTfR IgG3-Av alone (U266). Flow cytometry data showed that both IM-9 and U266 express high levels of surface TfR. IM-9 expresses higher levels of the hTfR compared with U266 cells; however, sensitivity to anti-hTfR IgG3-Av is not necessarily dependent on hTfR expression levels. We have previously tested a panel of cell lines and hTfR expression does not always correlate with sensitivity to anti-hTfR IgG3-Av. 7 Our preliminary analysis of myeloma cells, isolated from the bone marrow aspirates of two patients, showed that anti-hTfR IgG3/b-SO6 also enhanced the cytotoxicity of the fusion protein alone in these primary tumor isolates. However, a larger patient population will need to be tested to define the variability of these effects on cells from patients with multiple myeloma.
This study also showed the high stability of the anti-hTfR IgG3-Av/b-SO6 complexes. These complexes were incubated in RMPI 1640 without a loss of activity for up to 2 days. Only a slight loss of activity was observed after a 6-day incubation. Interestingly, RPMI contains 0.2 mg/L (820 nmol/L) of biotin. The mean concentration of biotin in normal human serum is 244 F 61 pmol/L (32). Thus, the biotin concentration in RPMI is over 3,000-fold higher than that of normal human serum. Our results show that the complexes are stable even in such high concentrations of free biotin.
We show that anti-hTfR IgG3-Av alone activated caspase-2, caspase-3, caspase-8, and caspase-9 at late time points in the sensitive cell line IM-9. A previous study showed that anti-hTfR IgG3-Av induced caspase-3, caspase-8, and caspase-9 activities in ARH-77 (another EBV-transformed lymphoblastoid cell line; ref. 4). However, no major difference was found in the timing of activation and the identification of a specific pathway of cell death remained elusive. Alternatively, multiple apoptotic pathways may be simultaneously activated. This study suggests that caspase-2 may be a key player in anti-hTfR IgG3-Avinduced cell death. Anti-hTfR IgG3-Av/b-SO6 also induces apoptosis and activates caspase-2, caspase-3, caspase-8, and caspase-9 in both anti-hTfR IgG3-Av sensitive (IM-9) and resistant (U266) cell lines. However, caspase-2 is activated first and at higher levels in IM-9 cells. Caspase-2 and caspase-3 are activated with similar kinetics and at similar levels in U266 cells. Activation of caspase-3 by saporin has been previously shown (10) . In IM-9 cells treated with antihTfR IgG3-Av/b-SO6, caspase activation occurs more rapidly than in cells treated with anti-hTfR IgG3-Av alone. Caspase-2 is a unique caspase that contains properties of both initiator and executioner caspases (reviewed in ref. 33) . Caspase-2 is activated in response to UV irradiation, cytokine deprivation, growth factor withdrawal, and DNA-damaging agents such as etoposide and cisplatin (33) . How caspase-2 is activated upon treatment with antihTfR IgG3-Av alone, or conjugated to b-SO6, remains to be determined. Z-VAD-FMK effectively blocked Fas-mediated cell death; however, it was unable to block the cell death induced by anti-hTfR IgG3-Av/b-SO6. This suggests that anti-hTfR IgG3-Av/b-SO6 induces, at least in part, a caspase-independent mode of cell death. Malignant cells often harbor defects in the apoptotic machinery that allow them to escape the cell death induced by many therapeutics (34 -36) . However, therapies that activate alternative forms of cell death, including caspase-independent cell death, may help to overcome this problem. Anti-hTfR IgG3-Av/ b-SO6 may activate multiple cell death pathways simultaneously. Inhibition of caspase activation does not always provide protection from the death stimulus and often reveals or enhances an underlying caspase-independent cell death pathway (34) . Induction of multiple cell death pathways may provide an advantage for anti-hTfR IgG3-Av/b-SO6 treatment by making it more difficult for the tumor to escape the cell death induced by the treatment.
We have previously shown that anti-hTfR IgG3-Av disrupts the normal recycling of the hTfR and forces it into the lysosomal compartment where it is presumably rapidly degraded (4). This observation raises a concern that the biotinylated protein toxin may also be rapidly degraded. However, there seems to be some leakage of this transport pathway or an alternative trafficking mechanism that enables enough of the saporin toxin to escape and reach the cytoplasm where it can effectively inhibit protein synthesis. In addition, saporin is highly stable and is resistant to denaturation, high temperature, and proteolysis (37) . The mechanism of how saporin escapes the endocytic pathway and reaches the cytoplasm is not known. Further studies are needed to determine how saporin reaches the cytoplasm of targeted cells. However, the successful delivery of b-SO6 suggests that other cytotoxic agents can also be delivered into cancer cells by anti-hTfR IgG3-Av.
Another concern in targeting the hTfR is the potential nonspecific toxicity due to the expression of the hTfR on a variety of normal tissues. We have recently shown that anti-hTfR IgG3-Av targets hTfR1 and not hTfR2. 6 The pattern of tissue expression of the two proteins is different. hTfR2 expression is limited to hepatocytes and enterocytes of the small intestine (1). hTfR1 is expressed at low levels on most cell types and is expressed at higher levels on cells with an elevated proliferative activity (such as the basal epidermis and intestinal epithelium) or cells that require high amounts of iron (such as erythroid progenitors that need iron for heme synthesis; ref. 1). Pluripotent hematopoietic progenitors do not express detectable levels of the hTfR (38 -40) . In fact, our flow cytometry data show that there is a population of CD34 + cells that express little or no TfR as evidenced by the significant overlap with the negative control peak. A second peak is also present, indicating that there are CD34 + cells that express the TfR. This is consistent with previous studies that detect TfR expression on committed progenitors (41, 42) .
In the present studies, we have shown that treatment with anti-hTfR IgG3-Av alone showed no toxic effects on hematopoiesis. However, anti-hTfR IgG3-Av/b-SO6 was toxic to all types of colonies tested. This is consistent with the results observed using another immunotoxin consisting of SO6 chemically conjugated to the murine IgG1 antihTfR antibody B3/25 (43) . This study showed toxicity to colony-forming unit -granulocyte/macrophage and burstforming -erythroid, with progenitors of the erythroid lineage being more sensitive to the effects of the immunotoxin. This is also consistent with our data and is expected because erythroid progenitors express high levels of the hTfR (1, 39) . Saporin immunotoxins targeting B-cell antigens have also shown toxicity to hematopoietic progenitors (44, 45) . It is important to note that the colony-forming assay tests toxicity on committed progenitors of each lineage. Less mature progenitors (pluripotent) can be distinguished from these committed ones by cell surface antigen expression, including the lack of hTfR expression on the less mature progenitors (39, 46) . These less mature progenitor cells occur in the bone marrow at very low frequency, estimated to be 0.05% to 0.1% of total nucleated bone marrow cells (47) or about one cell per 2 Â 10 4 human bone marrow cells (48) , making it difficult to test toxicity on these cells. Although there is some toxicity to the committed progenitors, anti-hTfR IgG3-Av/b-SO6 is expected to have little to no toxicity on the less mature progenitors due to the lack of hTfR expression (38 -40); thus, the committed progenitors could be repopulated.
The hTfR is dramatically increased on the surface of malignant cells (1) , which suggests that these malignant cells may be more vulnerable than normal cells to immunotoxin targeting through the hTfR. In fact, clinical trials on the efficacy of a hTfR-targeted conjugate consisting of transferrin and CRM107, a mutated form of the inhibitor or protein synthesis toxin secreted by the bacterium Corynebacterium diphtheria, support this hypothesis. Local injection of transferrin-CRM107 (TransMID, Xenova Group plc) has shown dramatic effects against brain cancer in phase I and phase II clinical trials, with minimal side effects (49) . Although high concentrations of 454A12-RTA showed central nervous system toxicity, a therapeutic window did exist and tumoricidal concentrations were safely reached by intraventricular injections of 454A12-RTA. Central nervous system toxicity was also observed in ovarian cancer patients treated i.p. with high doses of 454A12-RTA, whereas no toxicities were observed at low doses (50) . Systemic injection of TfR-targeted conjugates have also shown in vivo efficacy for anticancer treatment (51 -53) . In fact, human transferrin conjugated to cisplatin showed dramatic effects in two of five patients with advanced stages of breast cancer (51) .
To construct the antibody-avidin fusion protein, we decided to use human IgG3 due to its unique extended hinge region that provides spacing and flexibility (54) , thereby facilitating simultaneous binding of antigen and biotinylated compounds. In fact, IgG3 is the most flexible human IgG (55) . IgG3 is also effective in complement activation (56) and it binds all three FcgRs (56, 57) . Moreover, fusing proteins after the CH3 domain of human IgG3 does not result in the loss of Fc effector functions (58) . Further studies are needed do determine the activity and relevance of the Fc effector functions of anti-hTfR IgG3-Av. A concern that arises with the potential use of anti-hTfR IgG3-Av/b-SO6 complex as a therapeutic agent is its possible immunogenicity in patients. A phase I clinical trial conducted with a murine monoclonal anti-CD30 antibody conjugated to SO6 for the treatment of refractory Hodgkin's disease showed transient tumor regression (14) . However, the development of human antibodies against both the antibody and the toxin portion of the molecule limited the efficacy of the immunotoxin. Another phase I clinical trial using an immunotoxin consisting of murine monoclonal bispecific antibodies (Fab ¶ 2 ) with one arm directed against SO6 and one at CD22 on the surface of B cells for the treatment of B-cell lymphoma has also been conducted (15) . Five patients were included in the study and all showed transient responses to the treatment. Only one of the five patients developed human anti-mouse antibodies to the antibody portion of the immunotoxin as well as human antitoxin antibodies to SO6. This immunotoxin showed less immunogenicity than the full murine monoclonal antibody tested in the first clinical trial. Because our antibody fusion protein was constructed using human Fc regions, it is expected to show not only decreased immunogenicity but also enhanced cytotoxicity due to the activation of human effector functions and increased half-life in circulation (58) . The avidin portion of the molecule could also be immunogenic. Because oral antigens are known to induce tolerance (59), avidin was chosen for this study because it is expected to be less immunogenic compared with the bacterial protein streptavidin due to the human consumption of chicken eggs. The plant toxin b-SO6 is expected to be immunogenic in humans after multiple administrations. However, administration of immunosuppressive agents before or in combination with immunotoxins is expected to prevent the induction of antitoxin antibodies (60) . For example, it may be possible to treat patients with rituximab (anti-CD20 chimeric antibody: Rituxan; Genentech, Inc., and IDEC Pharmaceutical Corporation), which is in clinical use for the treatment of B cell non -Hodgkin's lymphoma, to knockout B cells and prevent a humoral response with the subsequent anti-hTfR IgG3-Av/b-SO6 treatment (60). The B cells would then be repopulated upon treatment cessation. It is also possible that immunogenicity would be low or absent when patients have an impaired immune response, such as cases of hematologic malignancies including multiple myeloma (61) and lymphoma (60) .
It is also possible that the immunogenicity of the antihTfR IgG3-Av/b-SO6 complex can be decreased by using an alternative biotinylated cytotoxic protein from human origin, such as the human eosinophil-derived neurotoxin, which is a part of the RNase A superfamily (62) or human perforin (63) . It is important to note, however, that toxic human proteins are in general several orders of magnitude less toxic than traditional bacterial or plant toxins (60) . It is also possible to use anti-hTfR IgG3-Av in a gene therapy approach by conjugating it to a biotinylated carrier, such as a liposome containing a therapeutic gene. This approach to gene delivery through targeting of the TfR has been termed ''transferrinfection'' (64) . The saporin gene has already been shown to be a suitable candidate gene for this purpose (65) . Specificity could be further enhanced by delivery of the saporin gene under the control of a cell-specific promoter, such as the immunoglobulin promoter to target malignant B cells. The p53 gene could also be delivered into tumor cells by targeting of the hTfR to restore expression of wildtype p53 (66) . This could sensitize tumor cells to other traditional therapies such as radiation (67) . Malignant cells could also be sensitized to cell death through the delivery of antisense oligonucleotides. In fact, antisense oligonucleotides to the antiapoptotic protein Bcl-2 delivered by transferrin-conjugated liposomes resulted in a 10-fold increase in daunorubicin toxicity in vitro (68) . This strategy has also been used to deliver antisense oligonucleotides to a class folate receptor, another transmembrane receptor involved in cell growth (69) . Delivery of these oligonucleotides sensitized breast cancer cells to doxorubicin treatment in vitro.
The present study provides the initial proof-of-principle that the antibody fusion protein anti-hTfR IgG3-Av is capable of a two-pronged attack through its intrinsic cytotoxic activity and its ability to deliver an active biotinylated toxin into malignant B cells. We also showed that the delivery of a cytotoxic agent by the fusion protein overcomes resistance in cells that show low sensitivity to the fusion protein alone. Anti-hTfR IgG3-Av may be used as a universal vector to deliver a wide variety of therapeutic molecules (including other toxins or chemotherapeutic drugs) in addition to saporin, increasing its versatility as a therapeutic agent. In addition, we anticipate that the utility of this therapeutic will not be restricted to the elimination of myeloma cells in vivo, but that it can also be used for in vitro approaches, including the efficient purging of myeloma cells for use in autologous transplantation in patients with multiple myeloma. We would like to stress that the effect of the results obtained from the present studies is not restricted to multiple myeloma. Similar approaches can be applied to other hematopoietic malignancies as well as other tumor types.
